Cancer Family
Nervous System Neoplasm
CI-CAN-00000038Explore in graph →
Non-malignant1,523 active trials9 approved drugs210 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000038Explore in graph →
Clinical trials
5,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07284069 | Senicapoc and Perampanel for Newly Diagnosed Glioblastoma(SENIPERA) | recruiting | Early Phase 1 | 36 | Aarhus University HospitalOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT06636162 | Window of Opportunity Study of DSP-0390 in Gliomas | recruiting | Early Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05091866 | Natural Progesterone for the Treatment of Recurrent Glioblastoma | terminated | Early Phase 1 | 4 | Emory UniversityOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07568366 | AI in Endoscopic Transsphenoidal Surgery | not yet recruiting | Early Phase 1 | 30 | University College, LondonOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06810336 | Pain Control and Quality of Recovery After Intravenous Methadone Versus Intravenous Remifentanil in Craniotomy Surgery | recruiting | Early Phase 1 | 40 | University of VirginiaOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07017816 | A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.(JACOB) | recruiting | Early Phase 1 | 18 | Children's National Research InstituteOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07538128 | Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma | recruiting | Early Phase 1 | 10 | Huashan HospitalOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT03163368 | Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors | active not recruiting | Early Phase 1 | 25 | Cedars-Sinai Medical CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04656535 | AB154 Combined With AB122 for Recurrent Glioblastoma | active not recruiting | Early Phase 1 | 46 | Yale UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03684980 | LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma | active not recruiting | Early Phase 1 | 58 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05704933 | Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases | completed | Early Phase 1 | 1 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT04040088 | An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors | active not recruiting | Early Phase 1 | 20 | Mayo ClinicOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04655404 | A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | recruiting | Early Phase 1 | 15 | Nationwide Children's HospitalOTHER | 5 | Mar 18, 2026 | clinicaltrials |
| NCT05577416 | A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma(AB-218-IIT-201) | completed | Early Phase 1 | 14 | Melbourne HealthOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05076513 | Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma | active not recruiting | Early Phase 1 | 42 | Nader SanaiOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05182905 | AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients | active not recruiting | Early Phase 1 | 97 | Nader SanaiOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT02933736 | Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients | active not recruiting | Early Phase 1 | 48 | Nader SanaiOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04391595 | LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients | completed | Early Phase 1 | 42 | Nader SanaiOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05636540 | In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma | recruiting | Early Phase 1 | 30 | Heather WachtelOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03970226 | Tocilizumab in Children With ACP | active not recruiting | Early Phase 1 | 9 | University of Colorado, DenverOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04173104 | PET and MRI Imaging of Brain Tumors Using [18F]PARPi | completed | Early Phase 1 | 5 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT04825275 | Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial | terminated | Early Phase 1 | 7 | Milton S. Hershey Medical CenterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04869449 | Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas | terminated | Early Phase 1 | 1 | Milton S. Hershey Medical CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06829173 | Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas | recruiting | Early Phase 1 | 39 | NYU Langone HealthOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT06645808 | PET-imaging of Two Vartumabs in Patients With Solid Tumors(VARTUTRACE) | recruiting | Early Phase 1 | 32 | Var2 PharmaceuticalsINDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT05423210 | Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme | recruiting | Early Phase 1 | 12 | Stony Brook UniversityOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT05798507 | Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma | active not recruiting | Early Phase 1 | 14 | Emory UniversityOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT05432375 | Study of Tinostamustine for Adjuvant Treatment of Glioblastoma | completed | Early Phase 1 | 10 | Mundipharma Research LimitedINDUSTRY | 2 | Dec 10, 2025 | clinicaltrials |
| NCT07077616 | Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma.(TAMAVAQTM) | recruiting | Early Phase 1 | 29 | Biogenea Pharmaceuticals Ltd.INDUSTRY | 1 | Dec 8, 2025 | clinicaltrials |
| NCT02282917 | Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma | terminated | Early Phase 1 | 7 | Massachusetts Eye and Ear InfirmaryOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT05553041 | 18F-Fluciclovine PET-MRI in High-grade Glioma | recruiting | Early Phase 1 | 30 | Children's Hospital of PhiladelphiaOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06209567 | A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors | active not recruiting | Early Phase 1 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07254104 | Clinical Evaluation of [68Ga]Ga-NOTA-RF PET Imaging Targeting RFVT3 in Patients With Pituitary Tumors | enrolling by invitation | Early Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07244666 | Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma | not yet recruiting | Early Phase 1 | 36 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06072586 | A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions | recruiting | Early Phase 1 | 82 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT05045027 | Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma | active not recruiting | Early Phase 1 | 36 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT05717153 | Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma | recruiting | Early Phase 1 | 18 | Mayo ClinicOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT04424966 | Infigratinib in Recurrent High-Grade Glioma Patients | terminated | Early Phase 1 | 7 | Nader SanaiOTHER | 1 | Oct 24, 2025 | clinicaltrials |
| NCT04712721 | Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. | terminated | Early Phase 1 | 14 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 10, 2025 | clinicaltrials |
| NCT02245997 | Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma | completed | Early Phase 1 | 78 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT05634707 | Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT) | active not recruiting | Early Phase 1 | 10 | Duke UniversityOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT06328686 | Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases | recruiting | Early Phase 1 | 10 | Emory UniversityOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07172178 | γδ T-PD-1 Ab Cells in the Treatment of Malignant Meningioma | not yet recruiting | Early Phase 1 | 12 | Nanjing Medical UniversityOTHER | 0 | Sep 15, 2025 | clinicaltrials |
| NCT06552260 | A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma | recruiting | Early Phase 1 | 27 | Ugonma ChukwuekeOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT01165632 | Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma | completed | Early Phase 1 | 24 | Mayo ClinicOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT04074785 | Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6(SCCC-06319) | terminated | Early Phase 1 | 10 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT07067346 | Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma | recruiting | Early Phase 1 | 10 | Sichuan UniversityOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07090538 | GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma. | not yet recruiting | Early Phase 1 | 10 | Chinese PLA General HospitalOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT04135807 | Implantable Microdevice In Primary Brain Tumors | recruiting | Early Phase 1 | 12 | Oliver JonasOTHER | 1 | Jul 23, 2025 | clinicaltrials |
Data updated 22 days agoSource updated May 7, 2026source: clinicaltrials